Analysis of CPI-100: An Investigational Nanoscale Coordination Polymer Therapeutic

1.0 Introduction

CPI-100 is an investigational nanomedicine identified as being under development by Coordination Pharmaceuticals, Inc. (CPI).[1] This therapeutic candidate is formulated using CPI's proprietary nanoscale coordination polymer (NCP) platform technology, suggesting a delivery system based on nanotechnology principles.[1] Development progressed to early-stage human testing, with a Phase 1 clinical trial initiated to evaluate CPI-100 in patients diagnosed with advanced solid tumors.[1] This report synthesizes the available information regarding CPI-100, its developer, the underlying technology platform, its proposed characteristics, and the status of its clinical investigation, based exclusively on the provided documentation.

2.0 Developer Profile: Coordination Pharmaceuticals, Inc. (CPI)

Coordination Pharmaceuticals, Inc. (CPI), headquartered in Elk Grove Village, Illinois, is identified as a privately held, clinical-stage biopharmaceutical company.[1] The company was founded by Dr. Wenbin Lin [1], who holds the position of James Franck Professor of Chemistry and Professor of Radiation & Cellular Oncology at the University of Chicago.[1] This strong academic connection underscores the company's origins in university-based research.